

A quantitative approach to aetiological triangulation: case study of beta-carotene and cardiovascular disease

Chin Yang Shapland

University of Bristol, Bristol, UK


25th of September

WCE

WORLD CONGRESS OF EPIDEMIOLOGY 2024



Triangulation in epidemiology




* With different and unrelated potential biases (preferably that point in opposite directions).

Our framework for combining multiple studies

Two types of variability between studies occurs during triangulation:

- *Relevance*: What causal effect the studies are estimating and how is it relevant to your causal question; and
- *Bias*: risk of bias in each study when estimating its causal effect.



Defining the target causal question

- The population
- Exposure measure
- Exposure window
- How exposure is to be summarized over time
- Outcome measure
- The statistical parameter to be estimated

Defining the target causal question

- The population: *Adults (above age 40) initially free from diagnosed CVD.*
- Exposure measure: *Dietary β -carotene*
- Exposure window: *Over 20-year period in mid-life*
- How exposure is to be summarized over time: *Average daily exposure*
- Outcome measure: *Cardiovascular disease (CVD) and secondary is coronary heart disease (CHD)*
- The statistical parameter to be estimated: *Risk ratio*

Relevance in identified evidence

Assess relevance

Map to
common
metric

From published manuscript

The population, exposure and outcome are generally derived easily from the eligibility criteria and outcome measurements used in the study.

The tricky part

Exposure window and how exposure is to be summarized over time.

May not have the exact causal question asked (i.e. different exposure or different population), but maybe can be mathematically converted? (for example, BMI vs percentage of fat mass).

Relevance

Relevance was assessed in terms of the six criteria. Transformations include;

Mendelian randomisation study

Convert log-transformed circulating β -carotene to per 5,000 $\mu\text{g}/\text{d}$ dietary β -carotene.

Randomised controlled trials


Convert different dosages to per 5,000 $\mu\text{g}/\text{d}$ dietary β -carotene.

Observational studies

Convert circulating β -carotene to per 5,000 $\mu\text{g}/\text{d}$ dietary β -carotene.


Bias in identified evidence

Depending on study design different risk of bias tools are available:



Each tool cover different bias domains and help the assessors to determine the extent of bias. We used *triangulate* R package for bias visualisation and adjustments.

Risk of bias - β -carotene and CHD



Conclusions

- Bias adjustment is prone to errors but not acknowledge bias and assume all effect estimates are unbiased are even more problematic.
- The future of triangulation is dependent on better and more consistent reporting.

Future work

- RoB for Mendelian randomisation
- Expert elicitation for priors
- Different estimands
- Guidance for relevance

Acknowledgements

Joshua A. Bell

Maria-Carolina Borges

Ana Goncalves Soares

George Davey Smith

Tom R. Gaunt

Deborah A. Lawlor

Luke A. McGuinness

Kate Tilling

Julian P.T. Higgins

Link to preprint

